GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Growth Rank

Piramal Pharma (NSE:PPLPHARMA) Growth Rank : 0 (As of May. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Growth Rank?

Piramal Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Piramal Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Piramal Pharma (NSE:PPLPHARMA) Business Description

Traded in Other Exchanges
Address
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines